A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

NCT06131372 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

626

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Type 2 Diabetes
Obesity

Interventions

DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Placebo

Sponsor

Novo Nordisk A/S